Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (251-260 of 441) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancerFrancisco J Esteva, Aysegul A Sahin, George Z Rassidakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancerThomas A Buchholz, Amit K Garg, Nitin Chakravarti, et al.
The Oncologist|May 26, 2021
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3Hope S Rugo, Massimo Cristofanilli, Sybille Loibl, et al.
Oncotarget|September 1, 2018
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applicationsAngela Toss, Federico Piacentini, Laura Cortesi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2011
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotypeJames M Reuben, Bang-Ning Lee, Hui Gao, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Critical Reviews in Oncology/Hematology|December 30, 2019
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)Lorenzo Gerratana, Qiang Zhang, Ami Naimish Shah, et al.
The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancerJonathan C Trent, Vicente Valero, Daniel J Booser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomesMassimo Cristofanilli, Ana Gonzalez-Angulo, Nour Sneige, et al.
Pageof 45

Showing results (251-260 of 441) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancerFrancisco J Esteva, Aysegul A Sahin, George Z Rassidakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancerThomas A Buchholz, Amit K Garg, Nitin Chakravarti, et al.
The Oncologist|May 26, 2021
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3Hope S Rugo, Massimo Cristofanilli, Sybille Loibl, et al.
Oncotarget|September 1, 2018
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applicationsAngela Toss, Federico Piacentini, Laura Cortesi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2011
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotypeJames M Reuben, Bang-Ning Lee, Hui Gao, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Critical Reviews in Oncology/Hematology|December 30, 2019
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)Lorenzo Gerratana, Qiang Zhang, Ami Naimish Shah, et al.
The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancerJonathan C Trent, Vicente Valero, Daniel J Booser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomesMassimo Cristofanilli, Ana Gonzalez-Angulo, Nour Sneige, et al.
Pageof 45